J. Herrmann

Oncology · European Heart Journal · 2020–2022

A researcher in the Science corpus: 4 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom J. Herrmann trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll
  2. M. Moasser

Papers from J. Herrmann's perspective

Ordered by how strongly the researchers J. Herrmann trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Cardiac dysfunction in the trastuzumab clinical trials experience. (Journal of Clinical Oncology)
  2. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. (Journal of the American College of Cardiology)
  3. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. (Journal of the American College of Cardiology)
  4. Congestive heart failure in patients treated with doxorubicin (Cancer)
  5. Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab (Circulation Cardiovascular Imaging)
  6. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. (New England Journal of Medicine)
  7. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy (Circulation)
  8. Risk of ischemic heart disease in women after radiotherapy for breast cancer. (New England Journal of Medicine)
  9. Long Term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals with Type 2 Diabetes: Four Year Results of the Look AHEAD Trial (Archives of Internal Medicine)
  10. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (Revista Española de Cardiología)

Their papers